ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: A prospective randomized pilot trial

Authors
Category Primary study
JournalANNALS OF TRANSPLANTATION
Year 2008
This article has no abstract
Epistemonikos ID: ecd700cf74360b53d587339d8162c859d174eab0
First added on: Nov 15, 2025